The study attempts to assess the therapeutic virtue of the optimized CXB-BLs in the management of Alzheimer’s disease in a mice model by studying the levels of cognitive dysfunction, acetylcholinesterase (AChE), Toll-like receptor (TLR4), and Interleukin-1β (IL-1β), in addition to the histological examination. This evidence concerns the gene ACHE and early-onset autosomal dominant Alzheimer disease.